A critical review of control strategies against meningococcal meningitis epidemics in sub-Saharan African countries

Infection

Volumn 30, Issue 4, 2002, Pages 216-224

  Chippaux, J P ^a   Debois, H ^b   Saliou, P ^b  

^a INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (Senegal)

^b SANOFI PASTEUR   (France)

Author keywords

Africa; Control; Immunization; Meningitis

Indexed keywords

POLYSACCHARIDE VACCINE;

DISEASE SEVERITY; EPIDEMIC MENINGITIS; HUMAN; IMMUNOGENICITY; IMMUNOLOGY; NEISSERIA MENINGITIDIS; REDUCTION; REVIEW; STATISTICAL MODEL; VACCINATION; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AFRICA; CARRIER STATE; CHILD; CHILD, PRESCHOOL; DEVELOPING COUNTRIES; GUIDELINE ADHERENCE; HEALTH POLICY; HUMANS; IMMUNIZATION SCHEDULE; INCIDENCE; INFANT; INFANT, NEWBORN; INFECTION CONTROL; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; RISK FACTORS; WORLD HEALTH ORGANIZATION;

EID: 0036387139     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-002-3012-2     Document Type: Review

References (67)

1. Saliou P, Rey JL, Stoeckel P: Une nouvelle stratégie de lutte contre les épidémies de méningites à méningocoques en Afrique Sahélienne. Bull Soc Path Ex 1978; 71: 34-45.
2. WHO: Lutte contre les épidémies de méningite à méningocoque. Guide pratique de l'OMS. Fondation Marcel Mérieux (eds): Lyon 1995, p. 72.
3. Greenwood BM, Bradley AK, Blakebrough IS, Whittle HC, Marshall TF de, Gilles HM: The immune response to a meningococcal polysaccharide vaccine in an African village. Trans R Soc Trop Med Hyg 1980; 74: 340-346.
4. Greenwood BM, Wali SS: Control of meningococcal infection in the African meningitis belt by selective vaccination. Lancet 1980; i: 729-732.
5. Gold R, Lepow ML, Goldschneider I, Gotschlich EC: Immune response of human infants to polysaccharide vaccines of group A and C Neisseria meningitidis. J Infect Dis 1977; 136: 31-35.
6. Poolman JT: Nouveaux vaccins méningococciques. Ann Inst Past/Actualités 1994; 5: 157-160.
7. Ceesay SJ, Allen SJ, Menon A, Todd JE, Cham K, Carlone GM, Turner SH, Gheesling LL, DeWitt W, Plikaytis BD, Greenwood B: Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization. J Infec Dis 1993; 167: 1212-1216.
8. Greenwood BM, Whittle HC, Bradley AK, Fayet MT, Gilles HM: The duration of the antibody response to meningococcal vaccination in an African village. Trans R Soc Trop Med Hyg 1980; 74: 756-760.
9. Reingold AL, Broome CV, Hightower A, Ajello GW, Bolan GA, Adamsbaum C, Jones EE, Phillips C, Tiendrebeogo H, Yada A: Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 1985; 2: 114-118.
10. Greenwood BM: The epidemiology of acute bacterial meningitis in tropical Africa. In: Williams JD, Burnie J (eds): Bacterial meningitis, Academic Press, London 1987, pp 61-91.
11. Lapeyssonnie L: La méningite cérébro-spinale en Afrique. Bull WHO 1963; 28: 1-114.
12. Robbins JB, Towne DW, Gotschlich EC, Schneerson R: "Love's labours lost": failure to implement mass vaccination against group A meningoccoccal meningitis in sub-Saharan Africa. Lancet 1997; 350: 880-882.
13. Chippaux JP, Campagne G, Djibo S, Hassane A, Kanta I, Cissé L: Possible impediment of preventive immunisation on the onset of meningococcal epidemics in the African meningitis belt. Ann Trop Med Parasitol 1999; 93: 505-510.
14. Hassan J, Massougbodji A, Chippaux JP, Massit B, Josse R: Meningococcal immunisation and protection from epidemics. Lancet 1998; 352: 407-408.
15. Moore PS, Plikaytis BD, Bolan GA, Oxtoby MJ, Yada A, Zougba A, Reingold AL, Broome CV: Detection of meningitis epidemics in Africa: a population-based analysis. Int J Epidemiol 1992; 21: 155-162.
16. Chabalier F de, Djingarey MH, Hassane A, Chippaux JP: Meningitis seasonal pattern in Africa and detection of epidemics: a retrospective study in Niger, 1990-98. Trans R Soc Trop Med Hyg 2000; 94: 664-668.
17. Chabalier F de, Hassane A, Chippaux JP: Evaluation of surveillance thresholds for prediction of meningitis epidemics using ongoing surveillance data at the district level, in Niger. Trans R Soc Trop Med Hyg 2000; 94: 251-252.
18. WHO: Detecting meningococcal meningitis epidemics in highly-endemic African countries. WHO recommendation. Week Epidemiol Rec 2000; 75: 306-309.
19. Campagne G, Chippaux JP, Djibo S, Issa O, Garba A: Epidémiologie et contrôle des méningites bactériennes chez les nourrissons à Niamey. Bull Soc Path Ex 1999; 92: 118-122.
20. Campagne G, Djibo S, Schuchat A, Ousséini A, Cissé L., Chippaux JP: Epidemiology of bacterial meningitis in Niamey, Niger, 1981-1996. Bull WHO 1999; 77: 499-508.
21. Peltola H, Kataja JM, Mäkelä PH: Shift in the age distribution of meningococcal disease as predictor of an epidemic? Lancet 1982; ii: 595-597.
22. Stephens DS: Uncloaking the meningococcus: dynamics of carriage and disease. Lancet 1999; 353: 941-942.
23. Higham JH: Meningococcal vaccine in sub-Saharan Africa. Lancet 1997; 350: 1707-1708.
24. Varaine F, Caugant DA, Riou JY, Kondé MK, Soga G, Nshimirimana D, Muhirwa G, Ott D, Hoiby EA, Fermon F, Moren A: Meningitidis outbreaks and vaccination strategy. Trans R Soc Trop Med Hyg 1997; 91: 3-7.
25. Diallo A, Etard JF, Chippaux JP: Burst of Neisseria meningitidis A outbreak after a 15 years free period. Am J Trop Med Hyg 2001; 65: 295.
26. Riou JY, Djibo S, Sangaré L, Lombart JP, Fagot P, Chippaux JP, Guibourdenche M: A predictable comeback: the second pandemic of infections due to Neisseria meningitidis serogroup A subgroup III-1 in Africa in 1995. Bull WHO 1996; 74: 181-187
27. Kwara A, Adegbola RA, Corrah PT, Weber M, Achtman M, Morelli G, Caugant D, Greenwood BM: Meningitis caused by a serogroup W135 clone of the ET-37 complex of Neisseria meningitis in West Africa. Trop Med Intern Health 1998; 3: 742-746.
28. WHO: Meningococcal disease, serogroup W135 (update). Week Epidemiol Rec 2001; 76: 157.
29. Spiegel A, Greindl Y, Lippeveld T, Decam C, Granga D, Nahor N, Bordonado JL, Sperber G, Yankalbé M, Baudon D: Effet de deux stratégies de vaccination sur l'évolution de l'épidémie de méningite à méningocoque A survenue à N'Djamena (Tchad) en 1988. Bull WHO 1993; 71: 311-315.
30. Goldschneider I, Gotschlich EC, Artenstein MS: Human immunity to the meningococcus. I. The role of antibodies. J Exp Med 1969; 129: 1307-1326.
31. Goldschneider I, Gotschlich EC, Artenstein MS: Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969; 129: 1327-1348.
32. Gold R, Goldschneider I, Lepow ML, Draper TF, Randolph M: Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis. 1978; 137: 112-121.
33. Campagne G, Garba A, Fabre P, Schuchat A, Ryall R, Boulanger D, Bybel M, Carlone G, Briantais P, Ivanoff B, Xerri B, Chippaux JP: Safety and immunogenicity of three doses of a Neisseria meningitidis A+C diphtheria conjugate vaccine in infants from Niger. Ped Infect Dis J 1999; 19: 144-150.
34. Gotschlich EC, Rey M, Triau R, Sparks KJ: Quantitative determination of the human immune response to immunization with meningococcal vaccines. J Clin Invest 1972; 51: 89-96.
35. Peltola H, Mäkelä PH, Käyhty H, Jousimies H, Herva E, Hällström K, Sivonen A, Renkonen OV, Pettay O, Karanko V, Ahvonen P, Sarna S: Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977; 297: 686-691.
36. Chippaux JP, Soula G, Campagne G, Rey M: Optimiser la riposte aux épidémies de méningite à méningocoque: rapport d'un atelier d'experts au CERMES de Niamey du 12 au 14 janvier 1998. Cahiers Santé 1998; 8: 245-248.
37. Perkins BA, Broome CV, Rosenstein NE, Schuchat A, Reingold AL: Meningococcal vaccine in sub-Saharan Africa. Lancet 1997; 350: 1708.
38. Saliou P, Stoeckel P, Lafaye A, Rey JL: Essais controlés du vaccin antiméningococcique polysaccharidique A en Afrique de l'Ouest Sahélienne (Haute Volta et Mali). Dev Biol Stand 1978; 41: 97-108.
39. Spiegel A, Quenel P, Sperber G, Meyran M: Evaluation de l'effi-cacité de la stratégie de vaccination systématique antiméningococcique chez les appelés de l'armée française. Cahiers Santé 1996; 6: 383-388.
40. Zangwill KM, Stout RW, Carlone GM, Pais L, Harekeh H, Mitchell S, Wolfe WH, Blackwood V, Plikaytis BD, Wenger JD: Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel. J Infect Dis 1994; 169: 847-852.
41. Nieminen T, Kayhty H, Kantele A: Circulating antibody secreting cells and humoral antibody response after parenteral immunization with a meningococcal polysaccharide vaccine. Scand J Infect Dis 1996; 28: 53-58.
42. Zhang Q, Choo S, Everard J, Jennings R, Finn A: Mucosal immune responses to meningococcal group C conjugate and group A and C polysaccharide vaccines in adolescents. Infect Immun 2000; 68: 2692-2697.
43. De Wals P, Dionne M, Douville-Fradet M, Boulianne N, Drapeau J, De Serres G: Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada. Bull WHO 1996; 74: 407-411.
44. Kriz P, Vlckova J, Bobak M: Targeted vaccination with meningococcal polysaccharide vaccine in one district of the Czech Republic. Epidemiol Infect 1995; 115: 411-418.
45. Salleras L, Dominguez A, Prats G: Control of serogroup C meningococcal meningitis by mass vaccination in Catalonia (Spain). Vaccine 1999: 17 (suppl 3): 56-60.
46. Hassan-King MK, Wall RA, Greenwood BM: Meningococcal carriage, meningococcal disease and vaccination. J Infect 1988; 16: 55-59.
47. Blakesbrough IS, Greenwood BM, Whittle HC, Bradley AK, Gilles HM: The epidemiology of infections due to Neisseria meningitidis and Neisseria lactamica in a northern Nigerian community. J Infect Dis 1982; 146: 626-636.
48. Koumaré B, Konaté M, Cissé M, Doumbia T: Etude du portage rhinopharyngé de Neisseria meningitidis sérogroupe C dans la collectivité autour des patients au Mali. A propos de 1033 sujets prélevés. Bull Soc Path Ex 1994; 87: 148-151.
49. Greenwood BM, Hassan-King M, Whittle HC: Prevention of secondary cases of meningococcal disease in household contacts by vaccination. Brit Med J 1978; 277: 1317-1319.
50. Wahdan MH, Sallam SA, Hassan MN, Abdel Gawad A, Rakha AS, Sippel JE, Hablas R, Sanborn WR, Kassem NM, Riad SM, Cvjetanovic B: A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria. Bull WHO 1977; 55: 645-651.
51. Takala AK, Santosham M, Almeido-Hill J, Wolff M, Newcomer W, Reid R, Kayhty H, Esko E, Makela PH: Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children. Pediatr Infect Dis J 1993; 12: 593-599.
52. Etienne J, Sperber G, Adamou A, Picq JJ: Notes épidémiologiques: les méningites à méningocoques du sérogroupe X à Niamey (Niger). Méd Trop 1990; 50: 227-229.
53. WHO: Meningococcal disease, serogroup W135 (update). Week Epidemiol Rec 2001; 76: 213-214.
54. Da Silva A, Parent du Chatelet I, Gaye AB, Dompnier JP, Seck I: Evaluation microéconomique des coûts opérationnels d'une campagne de masse préventive contre la méningite à méningocoque associant une vaccination contre la fièvre jaune au Sénégal en 1997: méthode et résultats. Cahiers Santé 2002 (in press).
55. Robbins JB, Schneerson R, Gotschlich EC: A rebuttal: epidemic and endemic meningococcal meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine. Pediatr Infect Dis J 2000; 19: 945-953.
56. Kaninda AV, Varaine F, Henkens M, Paquet C: Meningococcal vaccine in sub-Saharan Africa. Lancet 1997; 350: 1708.
57. Miller MA, Wenger J, Rosenstein N, Perkins B: Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa. Pediatr Infect Dis J 1999; 12: 1051-1059.
58. Bovier PA, Wyss K, Au HJ: A cost-effectiveness analysis of vaccination strategies against N. meningitidis meningitis in sub-Saharan African countries. Soc Sci Med 1999; 48: 1205-1220.
59. Woods CW, Sackey SO, Bugri S, Perkins BA, Rosenstein NE: Control of meningococcal disease in West Africa. Lancet 2000; 355: 1185.
60. Woods CW, Amstrong G, Sackey SO, Tetteh C, Bugri S, Perkins BA, Rosenstein NE: Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa. Lancet 2000; 355: 30-33.
61. Obaro S: Control of meningococcal disease in West Africa. Lancet 2000; 355: 1184-1185.
62. Lewis R, Varaine F, Belanger F, Nathan N, Diarra L: Control of meningococcal disease in West Africa. Lancet 2000; 355: 1185-1186.
63. Chabalier F de, Chippaux JP, Massougbodji A: Meningococcal immunisation in Ghana. Lancet 2000; 355: 2252-2253.
64. McDamien D, Boelaert M, Van Damme W, Van der Stuyft P: Meningococcal immunisation in Ghana. Lancet 2000; 355: 2252.
65. Parent du Chatelet I, Gessner BD, Silva A da: Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis. Vaccine 2001; 19: 3420-3431.
66. Smith AW, Bradley AK, Wall RA, McPherson B, Secka A, Dunn DT, Greenwood BM: Sequelae of epidemic meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1988; 82: 312-320.
67. WHO: Response to epidemic meningitis in Africa. Week Epidemiol Rec 1997; 72: 313-317.